T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs.
Fc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical application, in that they suppress graft rejection without the toxicity associated with conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced cytokine deviation and Th1 cell inactivation.
Smith
J A
JA
Ben May Institute for Cancer Research, Department of Pathology, University of Chicago, IL 60637, USA.
Bluestone
J A
JA
D000911:Antibodies, Monoclonal; D017252:CD3 Complex / Q000276:immunology*; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D011961:Receptors, Fc / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D016207:Cytokines; D011961:Receptors, Fc